| Page 47 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?

Author(s): 
Gorshein E, Weber UM, Gore S
Primary Author: 
Gorshein E
Journal Title: 
Expert Review of Hematology
Original Publication Date: 
Mar 2020

Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to

Bone Marrow Disease(s): 

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

Ruben Mesa, MD

Newly approved and investigational agents are joining ruxolitinib (Jakafi) for the treatment of myelofibrosis (MF) and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

At the 24th Annual International Congress on Hematologic Malignancies, hosted by Physicians’ Education Resource®, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib.

(continued)

Frequently Asked Questions: Coronavirus Disease 2019 (COVID-19) and Maintaining Mental Health

The outbreak of coronavirus disease 2019 (COVID-19) may be stressful for people and communities. Fear and anxiety about a disease can be overwhelming and cause strong emotions in adults and children. Information follows about how to cope with mental health and stress and anxiety during this time:

(Links follow)